Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.

ABSTRACT:

Background

This study assesses the incidence and timing of undetectable prostate-specific antigen (PSA) after radiotherapy (RT) ± androgen deprivation therapy (ADT) and its association with prostate cancer mortality.

Methods

This is a population-based study including 5299 men undergoing RT (2006-2020) in the Stockholm County, Sweden with all their PSA tests until death or emigration. The authors calculated incidence and timing of undetectable PSA (PSA ≤0.1 ng/mL) and used competing risk regression to evaluate the association of detectable PSA at 6 and 12 months with prostate cancer mortality (PCSM).

Results

Median follow-up for survivors was 81 (32, 130) months. PSA nadir values were reached before 6 and 12 months in 233 (23%) and 470 (36%) patients undergoing RT and

SUBMITTER: Falagario UG 

PROVIDER: S-EPMC12358021 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature